



O'ZBEKISTON HARBIY

2025-YIL, 3-SON

ТИОУИОТИ



«O‘zbekiston Harbiy Tibbiyoti» ilmiy-amaliy journali Ўзбекистон Республикаси Олий таълим, Фан ва инновациялар вазирлиги ҳузуридаги Олий аттестация комиссиясининг 2023 йил 29 августдаги № 01-07/1410/33 сонли маълумотномасига асосан, тиббиёт фанлари бўйича диссертациялар асосий илмий натижаларини чоп этиш тавсия этилган миллий илмий нашрлар рўйхатига киритилган.

Муассис:
ЎЗБЕКИСТОН РЕСПУБЛИКАСИ
ҚУРОЛЛИ КУЧЛАРИ ҲАРБИЙ
ТИББИЁТ АКАДЕМИЯСИ

Бош муҳаррир:
ЎЗБЕКИСТОН РЕСПУБЛИКАСИ МУДОФАА
ВАЗИРЛИГИ ТИББИЙ ТАЪМИНОТ БОШҚАРМАСИ
БОШЛИҒИ

Масъул котиб:
PhD., доц. ПЎЛАТОВА З.А.

**Ўзбекистон ҳарбий тиббиёти илмий-
амалий journalи Ўзбекистон
Республикаси Президенти
Администрацияси ҳузуридаги Ахборот
ва оммавий коммуникациялар
агентлигида 2022 йил 5 августдаги
1691-сонли гувоҳнома билан рўйхатга
олинган.**

Таҳририят манзили:
Тошкент шаҳри,
Зиёлилар қўчаси, 4-уй
Телефонлар: (71) 262-42-41

Таҳрир хайъати:
Т.ф.д., проф. Мухамедова М.Г.
Т.ф.д., проф. Миррахимова С.Ш.
Т.ф.д., проф. Эшбеков М.Э.
Т.ф.д., проф. Ибрагимов А.Ю.
Т.ф.д., проф. Каюмов У.К.
Т.ф.д., доц. Нуралиева Д.М.
Т.ф.д., доц. Хидоятова М.Р.
Т.ф.д., доц. Расулова З.Д.
Т.ф.д., доц. Раимкулова Н.Р.
Т.ф.д., Бозорова С.А.
Т.ф.д., Нагаева Г.А.
Т.ф.д., Абидова Д.Э.
Т.ф.н., доц. Рахимов А.Ф.
Т.ф.н., доц. Атамуродов Ш.И.
Т.ф.н., доц. Джаббаров А.М.
PhD., доц. Файзиева Д.Б.
PhD., доц. Махмудова Н.Р.
PhD., доц. Буранкулова Н.М.
PhD., доц. Пўлатова З.А.
PhD., Рустамов А.А.
PhD., Ибрагимова Н.Х.
Т.ф.н., Мирзаев Д.А.
Т.ф.н., Ачилов Ш.Ж.
Доц. Нуруллаев А.Ж.
Катта ўқитувчи Халимов Б.Х.
Дизайнер:
Райхона ОЧИЛОВА.

**Таҳририятга юборилган мақола ва
қўлёзмаларда берилган
маълумотларнинг ҳаққонийлиги ва
ишончлилиги учун
тўлиқ жавобгарликни муаллифлар
ўз зиммасига олади.**

**Журнал 20.08.2025 йилда босмахонага
топширилди.**

Қоғоз бичими 60x84 1/8.
Офсет усулида босилди.
Шартли 6,75 босма табок.
**“Ўзбекистон Республикаси Ҳарбий тиббиёт
академияси”нинг босмахонасида чоп
этилди**

10. Helal EH, El-Sayed M, et al. Assessment of pulmonary hypertension in patients diagnosed with chronic kidney disease. *Egypt J Bronchol*. 2024;18: (article 00337). [SpringerOpen](#)
11. Jin J, Xu X, et al. Meta-analysis of the correlation between pulmonary hypertension and echocardiographic parameters in CKD. *PeerJ*. 2024;12:e17245. [peerj.com+1](#)
12. de Pinto M, et al. The predictive role of the TAPSE/sPAP ratio for mortality and cardiovascular events in PH (systemic sclerosis cohort). *Front Cardiovasc Med*. 2024;11:1430903. [Frontiers](#)
13. Palacios-Moguel P, et al. The role of the TAPSE/sPAP ratio as a predictor of mortality in PAH. *Pulm Circ*. 2025; (in press). [ScienceDirect](#)
14. John T, et al. Prognostic relevance of TAPSE/sPAP in suspected PH with normal–mildly elevated mPAP. *Chest*. 2025; (ahead of print). [journal.chestnet.org](#)
15. Ghio S, et al. Clinical and prognostic role of tricuspid regurgitation in pulmonary hypertension (discussion includes TAPSE/sPAP). *Front Cardiovasc Med*. 2025;12: (article). [PMC](#)
16. **TRACLEER® (bosentan) US Prescribing Information**. U.S. FDA label update, 2023 — note on high protein binding and lack of removal by dialysis. [accessdata.fda.gov](#)
17. **TRACLEER® (bosentan) Product Monograph**. Janssen (Canada), July 30, 2024 — note: bosentan is not removed through dialysis; hepatic monitoring. [Janssen Labels](#)
18. Martínez-Díaz I, Martos N, Llorens-Cebrià C, et al. Endothelin Receptor Antagonists in Kidney Disease. *Int J Mol Sci*. 2023;24(4):3427. [MDPI+1](#)
19. Schiffrin EL. Endothelin System in Hypertension and Chronic Kidney Disease. *Hypertension*. 2024;81(6):e— (review). [AHA Journals](#)
20. Heerspink HJL, et al. Endothelin Receptor Antagonists for Kidney Protection: Lessons from Clinical Trials. *Clin J Am Soc Nephrol*. 2022;17(7): (review). [PMC](#)

UDC: 616.5-002-053.2:575.174

FREQUENCY OF OCCURRENCE OF ALLELES AND GENOTYPES OF CYP3A5 GENE POLYMORPHISM (A6986G) IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

**FAIZULLAEVA N.YA¹, ASHUROVA D.T.², RUZIBAKIEVA M.R¹,
SHERMATOVA Z.A.², RAUFOV A.A.¹**

¹*Institute of Human Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan*

²*Tashkent State Medical University*

Resume: The article presents the results of the analysis of the association of CYP3A5 polymorphism (A6986G) with the development of systemic lupus erythematosus (SLE) in children. Forty-five children with SLE and 72 healthy donors were examined. The frequency of the A allele was 88.9% in patients versus 93.75% in the control group, the differences are statistically insignificant ($p > 0.05$). The G/A genotype was found in 54.5% of patients and 47.2% of healthy people, and G/G in 35.6% of patients and 45.8% in the control, without significant differences ($p > 0.05$). The potential role of CYP3A5 polymorphism as a pharmacogenetic marker of sensitivity to glucocorticoid therapy in children with SLE is emphasized, which requires further studies with an expanded sample.

Keywords: systemic lupus erythematosus, children, CYP3A5, A6986G, glucocorticoids, pharmacogenetics, genotyping, immunogenetics.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by a wide range of clinical

manifestations and involvement of multiple organs and systems. The features of the course of SLE in children include a more aggressive

onset, high levels of immune activity, and frequent development of complications, which makes the search for prognostic markers especially important [1, 5, 11, 15]. In recent years, special attention has been paid to molecular genetic studies aimed at identifying predisposing factors for the development of SLE. Among them, polymorphisms of genes involved in xenobiotic metabolism, regulation of the immune response and apoptosis are considered as potential biomarkers of the risk and severity of the disease [2, 6, 9, 14].

The CYP3A5 gene encodes one of the key cytochrome P450 enzymes involved in the metabolism of a large number of drugs and endogenous substrates [3, 7, 10, 13]. The A6986G (rs776746) polymorphism affects the expression of the CYP3A5 enzyme, changing its activity, which may be important both in pharmacogenetics and in the pathogenesis of immune diseases, including SLE. The study of CYP3A5 (A6986G) polymorphism in children with SLE can contribute to a deeper understanding of the genetic mechanisms of predisposition to the disease and can potentially be used in predicting the course, choosing therapy and assessing the response to treatment [4, 8, 12].

Purpose of the study: to study the role of CYP3A5 gene polymorphism (A6986G) in the development of systemic lupus erythematosus in children.

Materials and methods of research:

We selected 45 children with SLE for molecular genetic studies. The control group

consisted of 72 practically healthy individuals of Uzbek nationality (data were provided by the leading researcher of the Department of Cellular Technologies of the Institute of Immunology and Human Genomics of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences Ruzibakieva M.R.)

The material for DNA extraction was 3-5 ml of venous blood from the cubital vein (Beckton-Dickinson vacutainers were used for blood collection) with an anticoagulant/preservative of 15% tripotassium EDTA (Ethendianin-tetraacetic acid). Genotyping of polymorphic regions of immune response genes was carried out by the polymerase chain reaction (PCR) method with allele-specific primers (NPF Litekh, Moscow) and electrophoretic detection of reaction products in agarose gel.

The distribution of genotypes in the studied polymorphic loci was studied using logistic regression analysis and checking for compliance with the Hardy-Weinberg equilibrium using the Fisher exact test. The correspondence of patients and control group individuals by gender and age was taken into account. Differences were considered statistically significant at $p < 0.05$.

Research results. In the first stage, we presented comparative data on the frequency of alleles A and G in patients with SLE and in the control group, and also analyzed the association with the risk of developing the disease.

Table1.

Frequency of occurrence of polymorphism of gene alleles CYP3A5 (A6986G) in the general sample and in the control group in children with SLE

Alleles	Cases	Controls	χ^2	p	OR	
	n = 45	n = 72			meaning.	95% CI
Allele G	0.889	0.938	1.75	0.19	0.53	0.21 – 1.37
Allele A	0.111	0.063			1.88	0.73 – 4.81

The results of the analysis of the frequency of alleles A and G of the CYP3A5 polymorphism (A6986G) in children with

SLE compared with the control group are presented in Table 4.2. It was found that the frequency of the allele G in the group of

patients was 88.9%, and in the control group - 93.8%. Despite the observed decrease in the frequency of the G allele in patients, the difference did not reach statistical significance ($\chi^2 = 1.75$; $p = 0.19$) (Table 1).

The relative risk (OR) estimate for carriage of the G allele was 0.53 (95% CI: 0.21–1.37), indicating a possible tendency

towards a protective role of this allele, but the results are not statistically significant. In contrast, carriage of the A allele is associated with OR = 1.88 (95% CI: 0.73–4.81), which may indicate a potential increase in the risk of developing SLE, but this association is also not statistically confirmed.




Fig. 1. Distribution of alleles in examined children with SLE

The frequency of the A allele of the CYP3A5 gene (A6986G) among children with SLE was 11.1%, while in the control group it was 6.2%. Despite the lack of statistical significance of differences ($\chi^2 = 1.75$; $p = 0.19$), there is a tendency towards an increased representation of the A allele in patients, which may indicate its potential role as a factor in genetic predisposition to the development of systemic lupus erythematosus (Fig. 1).

The relative risk (OR) calculation for carriage of the A allele showed a value of 1.88

(95% CI: 0.73–4.81), indicating an almost twofold increase in the chance of developing SLE in the presence of this allele. However, the wide confidence interval and $p > 0.05$ indicate the absence of a significant association, which is probably due to insufficient sample power.

Thus, the obtained data allow us to assume the possible involvement of the A allele in the pathogenesis of SLE in children, however, confirmation of this hypothesis requires further research on larger and ethnically homogeneous samples.

Table 2

Frequency of occurrence of gene polymorphism genotypes CYP3A5 (A6986G) in the general sample and in the control group in children with SLE

Genotypes	Cases	Controls	χ^2	p	OR	
	n = 45	n = 72			meaning.	95% CI

Genotype G/G	0.778	0.889			0.44	0.16 – 1.21
Genotype G/A	0.222	0.097	4.01	0.13	2.65	0.93 – 7.58
Genotype A/A	0.000	0.014			0.52	0.02 – 13.14

Analysis of the distribution of CYP3A5 (A6986G) genotypes among children with SLE and healthy donors showed differences in the frequency of variants. The G/G genotype was the most common in both groups, but its frequency was lower in patients with SLE (77.8%) compared to the control group (88.9%). Despite the tendency to a decrease in the proportion of this genotype among patients, the difference did not reach statistical significance ($\chi^2 = 4.01$; $p = 0.13$). At the same time, the calculation of the odds ratio (OR = 0.44; 95% CI: 0.16–1.21) may indicate a possible protective role of homozygous carriage of the G allele, although the results are not reliable (Table 2).

The frequency of the heterozygous genotype G/A was higher among patients (22.2% versus 9.7% in the control). The

calculation of OR = 2.65 (95% CI: 0.93–7.58) indicates an almost three-fold increase in the risk of developing SLE in the presence of a heterozygous combination, which may reflect the potential role of the A allele in the manifestation of the disease. However, despite the pronounced trend, statistical significance was also not achieved ($p > 0.05$), which may be due to the limited number of observations.

The homozygous genotype A/A was not detected in any patient with SLE, while in the control group its frequency was 1.4%. The obtained OR = 0.52 (95% CI: 0.02–13.14) with an extremely wide confidence interval does not allow us to draw reasonable conclusions about the significance of this genotype in the pathogenesis of the disease (Fig. 2).




Fig. 2. Distribution of genotypes in examined children with SLE

The obtained data indicate a tendency to an increase in the frequency of carriage of the A allele in patients with SLE, which can be considered as a potential factor of genetic predisposition to the disease. Considering that the A6986G polymorphism affects the splicing of the CYP3A5 gene mRNA, a

decrease in the expression of the functional protein in carriers of the A allele may have pathophysiological significance. The CYP3A5 enzyme, which belongs to the cytochrome P450 system, is involved not only in the metabolism of xenobiotics and drugs, but also in the biotransformation of steroid

hormones, including glucocorticoids. Glucocorticoids are known to play a key role in immunoregulation, inhibiting the production of proinflammatory cytokines and modulating the activity of T- and B-cells.

Decreased CYP3A5 activity in A-allele carriers may contribute to the accumulation of active forms of endogenous glucocorticoids or, conversely, to disruption of their metabolism, leading to an imbalance between anti-inflammatory and pro-inflammatory mediators. This, in turn, may enhance immune disorders characteristic of SLE. In addition, decreased CYP3A5 activity

may affect the pharmacokinetics of exogenous glucocorticoids widely used in the treatment of SLE, causing variability in the response to therapy: carriers of the A allele may have accelerated drug metabolism, which increases the risk of side effects, but may also contribute to a weaker therapeutic effect.

Thus, the identified differences in the frequency of CYP3A5 (A6986G) genotypes between children with SLE and the control group suggest the involvement of this gene in the pathogenesis of the disease due to changes in glucocorticoid metabolism and an indirect effect on immune homeostasis.

Table 3

Distribution of CYP3A5 gene polymorphism (A6986G) genotypes by severity of SLE

CYP3A5(A6986G)	1 degree n = 5	2 degree n = 24	3 degree n = 16	Totaln = 45
GG	0 (0.0%)	19 (79.2%)	16 (100.0%)	35 (77.8%)
GA	5 (100.0%)	5 (20.8%)	0 (0.0%)	10 (22.2%)
AA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

To assess the possible relationship between the CYP3A5 polymorphism (A6986G) and the clinical activity of systemic lupus erythematosus (SLE) in children, an analysis of the distribution of genotypes by the degree of disease activity was performed. According to the international classification (PRINTO, 2021), the first degree corresponds to the most severe course, the third - to the least pronounced activity of the process.

The results of the analysis showed a clear differentiation of genotypes by the degree of activity. In the group with the highest SLE activity (grade 1), 100% of patients had the heterozygous genotype G/A, while homozygous G/G was not found in this group. In the group with moderate activity (grade 2), the genotype G/G prevailed (79.2%), and G/A was found in 20.8% of patients. At the same time, in the group with the least pronounced activity (grade 3), exclusively all patients (100%) had the homozygous genotype G/G, and carriage of the A allele (G/A or A/A) was completely absent (Table 3).

Thus, carriage of the A allele (genotype G/A) is associated with a more severe course of the disease, while the homozygous for the G allele genotype G/G is

characteristic mainly of patients with milder clinical activity. Such a distribution can be explained by the pharmacogenetic effect of CYP3A5 polymorphism on the metabolism of glucocorticoids - key drugs in the therapy of SLE.

It is known that the A allele causes accelerated expression of the functional enzyme CYP3A5, which leads to faster metabolism and elimination of glucocorticoids from the body. This, in turn, can reduce their therapeutic effectiveness, especially in patients with an active inflammatory process. In conditions of insufficient duration of glucocorticoid action, autoimmune inflammation increases, which is clinically manifested by increased disease activity.

Particular attention should be paid to patients with the second degree of SLE activity and heterozygous genotype G/A. These children can be considered as a high-risk group for disease progression with transition to the first degree of activity, which is due to insufficient sensitivity to glucocorticoid therapy due to accelerated metabolism of the drug. Given this, these patients require more careful monitoring of immunoinflammatory parameters and possible correction of the treatment regimen.

Conclusion: Thus, the identified association between the G/A genotype and a more severe course of SLE emphasizes the importance of molecular genetic typing of CYP3A5 in children with SLE as a potential criterion for predicting response to therapy, assessing the risk of progression and developing personalized approaches to treatment.

List of references

1. Avar Aydin PO, Shan J, Brunner HI, Mitsnefes MM. Blood pressure control over time in childhood-onset systemic lupus erythematosus. //Lupus. 2018-27-657–664.
2. Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. // Pediatric nephrology. 2017-32(6)-1013-1021.
3. Cheng, J. Mirna-451a targets Ifn regulatory factor 8 for the progression of systemic lupus erythematosus // Inflammation. - 2017. - Vol.40. - P. 676-687.
4. Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease-monogenic lupus and beyond. // J Clin Med. 2020-9-712.
5. Fanouriakis, A. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. // Annals of the rheumatic diseases. - 2019. - Vol. 78, N 6. - P. 736-745.
6. Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus- a prospective validation study. // Lancet Rheumatol. 2019-1-e95–102.
7. Heshin. Bekenstein M, Trupin L, Yelin E, von Scheven E, Yazdany J, Lawson EF. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. // Semin Arthritis Rheum. 2019-49-267–272.
8. Jongvilaikasem P, Rianthavorn P. Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus. Eur J Pediatr. 2021-180-1431–1441.
9. Lythgoe H, Morgan T, Heaf E, Lloyd O, Al Abadi E, Armon K, et al. Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus-a longitudinal analysis. //Lupus. 2017-26-1285–1290.
10. Mosca, M. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria // Arthritis and rheumatology. - 2019. - Vol. 71, N 1. - P. 91-98.
11. Ponticelli C., Podestà MA. Calcineurin inhibitors in lupus nephritis. // J Nephrol. 2021- 34 (2)- 399-402.
12. Rodsaward P, Chottawornsak N, Suwanchote S, Rachayon M, Deekajorndech T, Wright HL, Edwards SW, Beresford MW, Rerknimitr P, Chiewchengchol D. The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. // Asian Pac J Allergy Immunol. 2019.
13. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. // Arthritis Rheumatol. 2020-72(4)-529-556.
14. Tektonidou, MG Survival in adults and children with systemic lupus erythematosus - a systematic review and Bayesian meta-analysis of studies from 1950 to 2016 // Annals of the rheumatic diseases. - 2017. - Vol. 76. - P. 2009-2016.
15. Weelden M, Queiroz LB, Lourenço DMR, Kozua K, Lourenço B, Silva CA. Alcohol, smoking and illicit drug use in pediatric systemic lupus erythematosus patients. // Rev Bras Reumatol. 2016-56-228–234.